Evaluation the level of human kallikrein-2-hk2, prostate specific antigen and some biochemical parameters in sera of patients with prostate disease

Mohammed Ghazi Shihab Hameed; Rafah Razooq Hameed Al-Samarrai; Mazin Anwer Yadgar Alobaidi

doi:10.53730/ijhs.v6nS9.12922

Authors

Mohammed Ghazi Shihab Hameed
fraji1996@gmail.com
Department of chemistry, College of education, University of Samarra, Iraq.
Rafah Razooq Hameed Al-Samarrai Department of applied chemistry, College of applied science, University of Samarra, Iraq
Mazin Anwer Yadgar Alobaidi College of medicine, University of Tikrit, Iraq

Keywords:

Prostate specific antigen, human kallikrein-2, fibrinogen gamma, total anti-oxidant capacity, vitamin D3

Abstract

The study was conducted on 90 serum samples of people with prostate diseases (G1-include 24 samples for patients with prostate cancer-PC , G2- include 24 samples for patients with benign prostatic hyperplasia-BPH and 22 samples for patients with prostatitis G3), compared with 20 samples for healthy individuals as control group. Prostate-specific antigen-PSA, human kallikrein-2-hK2, fibrinogen gamma-FGG, total anti-oxidant capacity-TAC, Vitamin D₃-VD₃. The results showed that the activity of PSA significantly elevated in G1 andG3 with no significant difference in G2, with significant increase in G1 for PSA and the hK2, FGG and TAC. so The results showed a significant increase in the group G2 in human kallikrein-2 with no significant difference in G3 compared with control group, and a significant increase in FGG levels in the group G2 and G3 compared with control group with no significant difference between G3, G1 with a significant increase in the group G2 and G3 in TAC levels compared with the control group , with significant decreased in VD3 levels in group G3 and no significant difference in groups G1, G2 compared with control group.

Downloads

Download data is not yet available.

References

Lebret T, Culine S, Davin JL, et al. Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist. The Aging Male. 2014 ; 1:17(2):87-93.

Miyahira AK, Sharp A, Ellis L etal. Prostate cancer research: the next generation; report from the 2019 Coffey‐Holden Prostate Cancer Academy Meeting. The Prostate. 2020;80(2):113-32.

Yeon A, Wang Y, Su S, Lo EM and Kim HL. Syngeneic murine model for prostate cancer using RM1 cells transfected with gp100. The Prostate. 2020;80(5):424-31.

SCOTT, Lesley J. Abiraterone acetate: A review in metastatic castration-resistant prostrate cancer. Drugs, 2017; 77(14): 1565-1576.

Aoun F, Marcelis Q and Roumeguère T: Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: T u. R R U. 2015; 7:125-136.

FOSTER HE, Dahm P, Kohler TS, etal. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. The Journal of urology. 2019; Sep;202(3):592-8.

Madersbacher S, Sampson N and Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019;65(5):458-64.

Capogrosso P and Salonia A, Montorsi F. Evaluation and nonsurgical management of benign prostatic hyperplasia. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier. 2021.

ROEHRBORN, Claus G. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Medical Clinics, 2011; 95(1): 87-100.‏

Patel ND and Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. IJU: journal of the Urological Society of India. 2014 ;30(2):170.

Kričković Z, Simatović M, Lukić D, Stanojević A, Škrbić V and Janjić G. Frequency of common complications during treatment of patients with benign prostate hyperplasia. Scripta Medica. 2020;51(1):48-53.

Roehrborn CG. Benign prostatic hyperplasia: an overview. Reviews in urology. 2005;7(Suppl 9):S3.

Rizzo A, Mollica V, Cimadamore A etal. Is there a role for immunotherapy in prostate cancer?. Cells. 2020 ; 8:9(9):2051.

Roumeguère T, Sfeir J, El Rassy E, etal. Oxidative stress and prostatic diseases. M C O. 2017 ; 1:7(5):723-8.

Khan FU, Ihsan AU, Khan HU etal. Comprehensive overview of prostatitis. Biomedicine & Pharmacotherapy. 2017 ; 1:94:1064-76.

Stamey TA and Stamey TA. Pathogenesis and treatment of urinary tract infections. Williams & Wilkins; 1980.

Drake M, Dodwad SJ, Davis J, Kao LS, Cao Y and Ko TC. Sex-related differences of acute and chronic pancreatitis in adults. Journal of Clinical Medicine. 2021 ; 15:10(2):300.

Barh D. Precision Medicine in Cancers and Non-Communicable Diseases. CRC Press; 2018 .

Salman WA. The Physiological Influence of Prostate size and Prostatic Specific Antigen (PSA) on The Concentrations of some Hormones and Biochemical Compounds for Males in Salah Alden Governorate. Journal of university of Anbar for pure science. 2016;10(3).

Pérez-Ibave DC, Burciaga-Flores CH and Elizondo-Riojas MÁ. Prostate-specific antigen (PSA) as a possible biomarker in non-prostatic cancer: A review. Cancer epidemiology. 2018 ; 1(54):48-55.

Hong D, Min JY, Min KB. Association between pyrethroids and prostate endpoints; stratified according to renal function. Environment International. 2021 ; 153:106489.

Wang JW and Man LB. Transurethral resection of the prostate stricture management. A J of A. 2020;22(2):140.

Mottet N, van den Bergh RC, Briers E etal. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. European urology. 2021;79(2):243-62.

Becker C, Piironen T, Pettersson K, Hugosson J and Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology. 2000;55(5):694-9.

Obiezu CV and Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer letters. 2005;224(1):1-22.

Nasser NJ, Sun K, Scanlon KM, Mishra MV and Molitoris JK. Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare. Cancers. 2022;14(4):864.

BECKER, Charlotte, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. The Journal of urology, 2000; 163.1: 311-316.‏

Cosma G, McArdle SE, Reeder S etal. Identifying the presence of prostate cancer in individuals with PSA levels< 20 ng mL- 1 using computational data extraction analysis of high dimensional peripheral blood flow cytometric phenotyping data. Frontiers in Immunology. 2017 ; 18:8:1771.

Lilja H, Ulmert D and Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat R Cancer. 2008 ;8(4):268-78.

Laino C. Rapid Rise in PSA May Signal Prostatitis. Oncology Times. 2006 May 25;28(10):27.

Pansadoro V, Emiliozzi P, Defidio L etal S. Prostate-specific antigen and prostatitis in men under fifty. European urology. 1996;30:24-7.

Nam RK, Diamandis EP, Toi A etal. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J of Clin Onc. 2000 ; 1:18(5):1036.

Albertsen PC, Fryback DG, Storer BE, Kolon TF and Fine J. Long-term survival among men with conservatively treated localized prostate cancer. Jama. 1995 ; 23:274(8):626-31.

Saedi MS, Hill TM, Kuus-Reichel K etal. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clinical chemistry. 1998; 1:44(10):2115-2119.

Bachour DM, Chahin E and Al-Fahoum S. Human kallikrein-2, prostate specific antigen and free-prostate specific antigen in combination to discriminate prostate cancer from benign diseases in Syrian patients. Asi Pac J of Cancer Prevention. 2015;16(16):7085-8.

Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai AR and Diamandis EP. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer research. 2003 ; 1:63(19):6543-6.

Magklara A, Scorilas A, Catalona WJ and Diamandis EP. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clinical chemistry. 1999 ; 1:45(11):1960-6.

Zhang M, Lin D, Luo C, Wei P, Cui K and Chen Z. Tissue Kallikrein Protects Rat Prostate against the Inflammatory Damage in a Chronic Autoimmune Prostatitis Model via Restoring Endothelial Function in a Bradykinin Receptor B2-Dependent Way. Oxidative medicine and cellular longevity. 2022 ; 1:2022.

Pinsky PF, Prorok PC and Kramer BS. Prostate Cancer Screening-A Perspective on the Current State of the Evidence. NEJ of med. 2017 ; 1:376(13):1285-9.

Gerner C, Steinkellner W, Holzmann K etal. Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis. Thrombosis and haemostasis. 2001;85(03):494-501.

Peng HH, Wang JN, Xiao LF etal. Elevated Serum FGG Levels Prognosticate and Promote the Disease Progression in Prostate Cancer. Frontiers in Genetics. 2021 ;29:12:651647.

Ma XK, Wen JY, Chen ZH etal. Clinical significance of plasma fibrinogen level in patients with prostate cancer.

Ghiselli A, Serafini M, Natella F and Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radical Biology and Medicine. 2000 ; 1:29(11):1106-14.

Mohammed ES, Al-Taie WF, Numan IT and Hussain SA. Changes in Serum Levels of Tumor Necrosis Factor-Alpha and Antioxidant status in Different Stages of Malignant Prostate Cancer Patients in Iraq. Iraqi Journal of Pharmaceutical Sciences (P-ISSN: 1683-3597, E-ISSN: 2521-3512). 2012;21(1):56-60.

Colston KA, COLSTON MJ and FELDMAN D. 1, 25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology. 1981 ; 1:108(3):1083-6.

Trump DL, Aragon-Ching JB. Vitamin D in prostate cancer. Asian j of andro. 2018 May;20(3):244.

Trump DL, Chadha MK, Sunga AY etal. Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU international. 2009;104(7):909-14.

Schwartz GG and Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer?(Hypothesis). Anticancer research. 1990 ; 1:10(5A):1307-11.